

Harvest and clarification

Performance of Emphaze AEX hybrid purifier in monoclonal antibody (mAb) purification process in mammalian cell cultures

Himanshu Nivsarkar, Alexei Voloshin, Jonathan F. Hester, Angelines Castro Forero and Gregory M. Jellum, Thermo Fisher Scientific, Inc.

Introduction

The Thermo Scientific™ Emphaze™ AEX Hybrid Purifier enables chromatographic clarification through the use of a hybrid design comprising a quaternary ammonium (Q) functional nonwoven chromatographic media paired with a size exclusion membrane. The Q-functional media is a high capacity hydrogel grafted to nonwoven. The downstream membrane is a highly asymmetric 0.2 micron nominally rated polymer membrane.

The Emphaze AEX hybrid purifier is designed to reduce DNA, HCP, endotoxin, and cell debris. It is typically positioned as the second stage of clarification after the primary cell capture step (for example, Centrifugation or Depth Filtration). The Emphaze AEX hybrid purifier delivers consistent, high purity clarified fluid to the capture chromatography operation. The reduction of

DNA, HCP, and cell debris early in the purification process may confer benefits across the Protein A column, such as higher product purity in the Protein A eluate, and reduced turbidity of the neutralized viral inactivation pool.

In this tech note, we describe the performance and benefits of the Emphaze AEX hybrid purifier in a typical monoclonal antibody purification process. We evaluate the performance in terms of turbidity reduction, HCP reduction, and DNA reduction at clarification, and its effect on Protein A column purification performance.

Product performance

Turbidity reduction

Experimental procedure. A non-mAb producing CHO cell concentrate, having an initial turbidity of 84 NTU, a DNA concentration of 1.6×10^8 pg/mL, and an HCP concentration of 3.9×10^5 ng/mL, was passed through an Emphaze AEX hybrid purifier BV8 capsule at a flux of 190 L/(m² h). Samples for turbidity, DNA, and HCP analysis were taken periodically throughout each run. In addition, the final pool samples were taken. The outlet turbidity is shown in Figure 1, the DNA reduction in Figure 2, and the HCP reduction in Figure 3.






Figure 1. Outlet turbidity as a function of throughput for Emphaze AEX hybrid purifier




Figure 2. DNA Reduction as a function of throughput for Emphaze AEX hybrid purifier.




Figure 3. HCP Reduction as a function of throughput for Emphaze AEX hybrid purifier.

Dynamic binding capacity for DNA

The DNA Dynamic Binding Capacity (DBC) of the Emphaze AEX hybrid purifier using pure challenges is shown in Figure 4 as a function of buffer type, and in Figure 5 as a function of pH and conductivity. Figure 5 shows a trend of increasing DNA DBC with increasing NaCl concentration in these pure challenges. (Note: The data presented are for information purpose only based on performance of product meeting all release criteria and should not be regarded as product specification. Results using low conductivity solutions (1.5 mS/cm) are for comparison only and are outside the recommended use conductivity range.)

Experimental procedure. Reference solutions with a known concentration of Calf Thymus DNA were prepared in the appropriate loading buffer. The DBC test was performed using an automated liquid chromatography system that continuously monitors the UV absorbance. The DBC was determined at 10% breakthrough relative to the UV absorbance of the DNA challenge solution. The samples were flushed with equilibration buffer at 5 BV/min until a constant UV baseline was achieved. Equilibration buffer had the same composition of the reference solution but contained no DNA. The Emphaze AEX hybrid purifier media composite was then challenged with the DNA solution at 5 BV/min.

Product recovery




Figure 4. DNA Dynamic Binding Capacity (DBC) of Emphaze AEX hybrid purifier as a function of buffer type. No additional sodium chloride was introduced during buffer preparation.




Figure 5. DNA Dynamic Binding Capacity (DBC) of Emphase AEX hybrid purifier as a function of pH and conductivity. Note: The data presented are for information purpose only based on performance of product meeting all release criteria and should not be regarded as product specification. Results using low conductivity solutions (1.5 mS/cm) are for comparison only and are outside the recommended use conductivity range.

The Emphase AEX hybrid purifier primarily uses an anion exchange mechanism for purification. This results in low nonspecific binding of the cationic product and consequently mAb recoveries > 95% can be attained.

Experimental procedure. Human IgG recovery was used as a model of mAb recovery by the Emphase AEX hybrid purifier. A human immunoglobulin G (IgG) challenge solution was prepared by dissolving 1.0 mg/mL of IgG and 100 mM of NaCl in 20 mM phosphate buffer, pH 7. An Emphase AEX hybrid purifier capsule was challenged with 380 L/m² of this challenge solution at a flux of 3.8 L/(m²-min). The resulting IgG recovery was 99.5%.

Enhanced Protein A column performance

The purification performance of the Protein A chromatography column may be enhanced by significantly reducing DNA and HCP load using Emphase AEX hybrid purifier in the upstream clarification process.

HCP reduction was evaluated in Experimental Procedure A discussed below. The HCP concentration was reduced by 24% when the centrate was processed through an Emphase AEX hybrid purifier. This is compared to only a 6% reduction with a Thermo Scientific depth filter. This higher level of clarified fluid purity resulted in an HCP concentration in the Protein A eluate 19 times lower for the Emphase AEX hybrid purifier case compared with the depth filter case.

Experimental Procedure A. A non-mAb producing CHO centrate having a turbidity of 84 NTU was spiked with 0.7 mg/mL human IgG (as a mAb simulant). The spiked centrate was clarified using either a depth filter or Emphase AEX hybrid purifier, then

loaded onto a Protein A column that was subsequently washed and eluted. An aggressive clean-in-place (CIP) procedure was performed on the Protein A column using 4 M guanidine HCl. HCP was quantified, using ELISA, at each of the numbered positions 1-4 in Figure 7 (post-centrifugation, post-clarification, post-elution from Protein A, and in the fluid recovered from the Protein A column during the CIP procedure).

DNA reduction was evaluated in Experimental Procedure B. Figure 8 shows the DNA concentration measured at each numbered step in the process sequence for cases in which the clarified




Figure 6. HCP concentrations in CHO harvest or centrate (1), clarified fluid (2), Protein A eluate (3), and clean-in-place fluid (4) when CHO harvest/centrate was clarified using either Thermo Scientific depth filter clarification (blue) or Emphase AEX hybrid purifier (red).

fluid was spiked with IgG. Whereas this experiment indicated no measurable reduction of DNA by the depth filter, Emphase AEX hybrid purifier reduced the DNA concentration in the CHO centrate by 3.9 LRV. This resulted in a cumulative DNA reduction of 5.9 LRV post-Protein A (a 3.5-log improvement in cumulative post-Protein A DNA reduction compared with depth filtration). These results indicate substantially better performance of the Protein A column in clearing DNA when the Emphase AEX hybrid purifier was used for upstream clarification, compared with the depth filter. In fact, the Emphase AEX hybrid purifier clarified fluid had a 1.5-log lower DNA concentration than the Protein A eluate for the depth filter.

DNA/protein complexes such as chromatin have been reported to facilitate co-elution of HCP with mAb from the Protein A column.^{1,2} These reports are consistent with the findings herein, showing that >4 log removal of DNA during clarification prior to Protein A chromatography can result in a many-fold reduction in HCP impurities in the Protein A pool.

Experimental Procedure B. A non-mAb producing CHO centrate was clarified using either a depth filter or Emphaze AEX hybrid purifier. The clarified fluid was then spiked with 1.0 mg/mL human IgG as a simulant for mAb. The IgG-spiked fluid was then loaded onto a Protein A column that was subsequently washed and eluted. An acid regeneration of the Protein A column was performed using 5 column volumes of citric acid buffer, pH 2.5. DNA was quantified by qPCR at each of the numbered positions 1-4 in Figure 8 (post-centrifugation, post-clarification, post-elution from Protein A, and in the fluid recovered from the Protein A column during acid regeneration).




Figure 7. DNA concentrations in CHO centrate (1), clarified fluid (2), protein A eluate (3), and acid regeneration fluid (4) when CHO centrate was clarified using either a Thermo Scientific depth filter clarification (blue) or Emphaze AEX hybrid purifier (red).

Enhanced Protein A column protection

The Emphaze AEX hybrid purifier provides protection of the valuable capture chromatography column by decreasing the contaminant load, resulting in measurably fewer column-bound impurities. This has the potential to enable less aggressive column cleaning procedures.


The data provided in Figure 6 demonstrates that using an Emphaze AEX hybrid purifier for clarification results in a substantial reduction of column-bound protein impurities as evidenced by the low HCP concentration in the regeneration fluid (CIP fluid). In this study the HCP concentration in the CIP fluid was only 26 ng/mL, which was 17 times lower than that resulting from a depth filter clarified load.

Similarly, as shown in Figure 7, the DNA concentration in the regeneration fluid was 2.7 logs lower for an Emphaze AEX hybrid purifier clarified load compared to depth filter clarified fluid, indicating substantially reduced column-bound DNA impurities after elution.

Summary

The Emphaze AEX hybrid purifier is a **“hybrid clarifier,”** a synthetic, clarifying product containing both a Q-functional anion exchange media and a fine particle reduction membrane.

- **Robust turbidity reduction.** The Emphaze AEX hybrid purifier provides consistent outlet turbidity < 5 NTU throughout the entirety of the clarification run, due to the high anion exchange capacity.
- **Substantial DNA reduction.** The Emphaze AEX hybrid purifier provides greater than 4 log DNA reduction.
- **Excellent mAb recovery.** The Emphaze AEX hybrid purifier’s chemically defined, cationic media has a very low nonspecific binding which provides excellent mAb recovery, typically >95%.
- **Enhanced performance of the Protein A column.** The Emphaze AEX hybrid purifier, when used in the upstream clarification stage, can substantially enhance purification performance of the Protein A chromatography column by significantly reducing DNA and HCP challenge load.
- **Enhanced protection of the Protein A column.** The Emphaze AEX hybrid purifier provides protection of the valuable capture chromatography column, resulting in substantially fewer column-bound impurities. This has the potential to enable less aggressive column cleaning procedures.



Conclusion

The Emphaze AEX hybrid purifier brings chromatographic clarification to the bioprocess. Specifically, this product is intended for use in the clarification of mammalian cell cultures as part of the purification of biopharmaceuticals, particularly monoclonal antibodies (mAbs). The Emphaze AEX hybrid purifier enables chromatographic clarification through the use of a hybrid media design comprising a Q-functional nonwoven chromatographic media paired with a size exclusion membrane. This enables simultaneous reduction of cell debris, DNA, HCP, and endotoxins. Reduction of key contaminants early in the process may simplify customers' processes by reducing multiple types of impurities in a single process step, which may lead to a better process economics.

References

1. H. T. Gan, J. Lee, S. M. A. Latiff, C. Chuah, P. Toh, W. Y. Lee & P. Gagnon; Characterization and removal of aggregates formed by nonspecific interaction of IgM monoclonal antibodies with chromatin catabolites during cell culture production; *Journal of Chromatography A* **2013**, 1291, 33-40.
2. P. Gagnon, F. Hensel, S. Lee & S. Zaidi; Chromatographic behavior of IgM:DNA complexes; *Journal of Chromatography A* **2011**, 1218, 2405-2412.

Intended Use: Single-use filter products are intended for use in biopharmaceutical processing applications of aqueous based pharmaceuticals (drugs) and vaccines in accordance with the product instructions and specifications, and cGMP requirements, where applicable.

Since there are many factors that can affect a product's use, the customer and user remain responsible for determining whether the Thermo Scientific product is suitable and appropriate for the user's specific application, including user conducting an appropriate risk assessment and evaluating the Thermo Scientific product in user's application.

Restrictions on Use: Thermo Fisher advises against the use of these Thermo Scientific products in any application other than the stated intended use(s), since other applications have not been evaluated by Thermo Fisher and may result in an unsafe or unintended condition. Do not use in any manner whereby the Thermo Scientific product, or any leachable from the Thermo Scientific product, may become part of or remains in a medical device that is regulated by any agency, and/or globally exemplary agencies, including but not limited to: a) FDA, b) European Medical Device Regulation (MDR), c) Japan Pharmaceuticals and Medical Devices Agency (PMDA) or in applications involving permanent implantation into the body; Life-sustaining medical applications; Applications requiring food contact compliance.

Technical Information: The technical information, guidance, and other statements contained in this document or otherwise provided by Thermo Fisher are based upon records, tests, or experience that Thermo Fisher believes to be reliable, but the accuracy, completeness, and representative nature of such information is not guaranteed. Such information is intended for people with knowledge and technical skills sufficient to assess and apply their own informed judgment to the information. No license under any Thermo Fisher or third-party intellectual property rights is granted or implied with this information.

Product Selection and Use: Many factors beyond Thermo Fisher's control and uniquely within user's knowledge and control can affect the use and performance of a Thermo Scientific product in a particular application. As a result, end-user is solely responsible for evaluating the product and determining whether it is appropriate and suitable for end-user's application. Failure to properly evaluate, select, and use a Thermo Scientific product and appropriate safety products, or to meet all applicable safety regulations, may result in injury, sickness, death, and/or harm to property.

 For more information, contact your Thermo Fisher Scientific sales representative or visit thermofisher.com/bioprocessfiltration

thermo scientific